Truist raised the firm’s price target on Exelixis (EXEL) to $51 from $49 and keeps a Buy rating on the shares after the company provided 2026 updated. The management reinforced its long-term strategy of building a scaled, multi-franchise oncology business, leveraging its commercial playbook from Cabo to replicate success across new tumor areas and modalities, the analyst tells investors in a research note. 2026 will be a pivotal year for Zanzalintinib and potential first commercialization, the firm added.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis reports preliminary FY25 revenue $2.32B, consensus $2.33B
- Exelixis sees FY26 revenue $2.525B-$2.625B, consensus $2.62B
- Exelixis price target raised to $52 from $49 at H.C. Wainwright
- Exelixis downgraded to Equal Weight from Overweight at Morgan Stanley
- Exelixis, Natera announce collaboration on STELLAR-316 trial